PETAL Consortium Survival Prognosticators and How Inflammation Impacts Hematopoiesis
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
PETAL Consortium Survival Prognosticators and How Inflammation Impacts Hematopoiesis
-
ナレーター：
-
著者：
概要
In this week's episode, Blood associate editor Dr. Laura Michaelis interviews Drs. Mark Sorial and Emmanuelle Passegue on their articles published in volume 147 issue 7 of Blood. Dr. Sorial discusses "Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium" where he and his team evaluated the prognostic significance of early relapse in a large retrospective cohort. They report a time to relapse of <12 months as a strong predictive factor independent of the prognostic index for T-cell lymphoma and histology, with results validated in 2 independent cohorts. Dr. Emmanuelle Passegue discusses "Inflammation perturbs hematopoiesis by remodeling specific compartments of the bone marrow niche". Using a combination of single-cell RNA sequencing profiling and flow cytometry, the team characterized the bone marrow niche compartments in mice subjected to inflammation. They show that inter-
feron-mediated inflammation preferentially targets central marrow leptin receptor–expressing mesenchymal cells, triggering cytokine release that affects monocyte dynamics in the bone marrow microenvironment.